<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>6(41)</volume><submitter>Liu D</submitter><pubmed_abstract>The development of drugs with rapid distribution in the kidney and long-term retention in the renal tubule is a breakthrough for enhanced treatment of acute kidney injury (AKI). Here, l-serine-modified chitosan (SC) was synthesized as a potential AKI kidney-targeting agent due to the native cationic property of chitosan and specific interaction between kidney injury molecule-1 (Kim-1) and serine. Results indicated that SC was rapidly accumulated and long-term retained in ischemia-reperfusion-induced AKI kidneys, especially in renal tubules, which was possibly due to the specific interactions between SC and Kim-1. SC-TK-SS31 was then prepared by conjugating SS31, a mitochondria-targeted antioxidant, to SC via reactive oxygen species (ROS)-sensitive thioketal linker. Because of the effective</pubmed_abstract><journal>Science advances</journal><pagination>eabb7422</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7546709</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>ROS-responsive chitosan-SS31 prodrug for AKI therapy via rapid distribution in the kidney and long-term retention in the renal tubule.</pubmed_title><pmcid>PMC7546709</pmcid><pubmed_authors>You Y</pubmed_authors><pubmed_authors>Qi J</pubmed_authors><pubmed_authors>Shen Q</pubmed_authors><pubmed_authors>Shu G</pubmed_authors><pubmed_authors>Chen M</pubmed_authors><pubmed_authors>Lou X</pubmed_authors><pubmed_authors>Du Y</pubmed_authors><pubmed_authors>Jiang S</pubmed_authors><pubmed_authors>Wang J</pubmed_authors><pubmed_authors>Yu H</pubmed_authors><pubmed_authors>Jin F</pubmed_authors><pubmed_authors>Sun M</pubmed_authors><pubmed_authors>Zhu M</pubmed_authors><pubmed_authors>Zhu L</pubmed_authors><pubmed_authors>Ying X</pubmed_authors><pubmed_authors>Liu D</pubmed_authors><pubmed_authors>Xu X</pubmed_authors></additional><is_claimable>false</is_claimable><name>ROS-responsive chitosan-SS31 prodrug for AKI therapy via rapid distribution in the kidney and long-term retention in the renal tubule.</name><description>The development of drugs with rapid distribution in the kidney and long-term retention in the renal tubule is a breakthrough for enhanced treatment of acute kidney injury (AKI). Here, l-serine-modified chitosan (SC) was synthesized as a potential AKI kidney-targeting agent due to the native cationic property of chitosan and specific interaction between kidney injury molecule-1 (Kim-1) and serine. Results indicated that SC was rapidly accumulated and long-term retained in ischemia-reperfusion-induced AKI kidneys, especially in renal tubules, which was possibly due to the specific interactions between SC and Kim-1. SC-TK-SS31 was then prepared by conjugating SS31, a mitochondria-targeted antioxidant, to SC via reactive oxygen species (ROS)-sensitive thioketal linker. Because of the effective</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Oct</publication><modification>2025-04-04T09:15:03.444Z</modification><creation>2020-10-29T10:54:16Z</creation></dates><accession>S-EPMC7546709</accession><cross_references><pubmed>33036968</pubmed><doi>10.1126/sciadv.abb7422</doi></cross_references></HashMap>